Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.

Veravas, Tymora team up in race for Alzheimer's blood test

By staff writers

January 13, 2020 -- Diagnostics company Veravas and biotechnology company Tymora Analytical Operations are collaborating on the development of a blood test for the early detection of biomarkers associated with Alzheimer's disease.

The companies believe that Veravas' sample prep technology and Tymora's extracellular vesicle enrichment technology are complementary. The goal is to develop a minimally invasive approach for measuring circulating biomarkers as an alternative to the current method of testing cerebrospinal fluid.

"Because current biomarker analysis procedures are long and cumbersome, there is a critical need for a novel minimally invasive and cost-effective diagnostic assay to facilitate routine screening and early detection of [Alzheimer's disease]," the companies said in a statement about the collaboration.

Veravas tackles biotin interference in lab tests
Veravas will showcase a portfolio of tests for research use for detecting and troubleshooting problems with interference from biotin, or vitamin B7, in...
AAIC update: Where blood-based dementia tests stand in 2019
Against the shadowy backdrop of multiple failed trials in Alzheimer's disease, hope springs eternal for a reliable, noninvasive blood test for dementia,...
Evidence builds for Alzheimer's beta-amyloid blood test
Blood-based biomarker testing for Alzheimer's disease performed well in two prospective studies for assessing beta-amyloid plaque buildup in the brain....
High cholesterol offers clues in early-onset Alzheimer's disease
People with the early-onset form of Alzheimer's disease also have elevated cholesterol, which may be related to variants in the apolipoprotein B gene,...

Copyright © 2020

Last Updated np 1/13/2020 2:41:47 PM